SecBot SecBot

ABCL drug pipeline

AbCellera Biologics Inc. · 7 rated drugs
$11.49
−1.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
7
7 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Feb 2027
    ABCL635
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2
Time to marketPhase 3 is planned to begin in 2027. Assuming a multi-year Phase 3 program followed by FDA review, potential approval would likely be 2029-2030 at the earliest, barring accelerated development.

ABCL635 Updated Nov 9

What to watch

The next major catalyst for ABCL635 is the planned Phase 3 start in 2027, which the company confirmed on its Q3 2026 earnings call. Positive Phase 2 data (83% vs 33% placebo reduction in hot flash frequency) has already been reported, so the stock's next binary event is likely years away. Watch for FDA feedback on Phase 3 trial design and any partnership/licensing deals that could validate the asset's value.

Bull case
  • Phase 2 data showed an 83% reduction in moderate-to-severe hot flash frequency versus 33% on placebo after a single dose, which the company describes as best-in-class.
  • ABCL635 offers a differentiated monthly injectable dosing regimen versus daily oral pills (Veozah, Lynkuet), potentially improving compliance and convenience.
  • The company raised $200M in an oversubscribed offering after Phase 2 data, providing a strong cash runway to fund Phase 3 development.
Bear case
  • ABCL635 faces entrenched oral competitors already on the market: Astellas' Veozah (fezolinetant) and Bayer's Lynkuet (elinzanetant), both daily pills approved for the same indication.
  • As an injectable antibody, ABCL635 may face payer and patient adoption hurdles versus convenient daily oral pills, even with monthly dosing.
  • The company is still pre-revenue on its own pipeline and posted a Q3 2026 operating loss of $40.8M, requiring continued capital raises beyond the $200M oversubscribed offering.
● neutral
Impact
PhasePhase 1
Time to marketNot applicable; development has been paused with no timeline for resumption.

ABCL575 anti-OX40L monoclonal antibody Updated Nov 10

What to watch

AbCellera announced on its Q3 2026 earnings call (November 9, 2026) that it is shelving further development of ABCL575 for now, while prioritizing ABCL635 (hot flash treatment) for late-stage development. Investors should watch whether AbCellera ever resumes ABCL575 development or partners it out, but near-term attention is on ABCL635's Phase 2-to-Phase 3 transition in 2027.

Bull case
  • OX40L is a validated target in atopic dermatitis; approved drugs targeting the OX40 pathway (like amlitelimab) have shown efficacy, suggesting the mechanism is sound.
  • Preclinical data presented at the 2025 SID Annual Meeting showed potent inhibition of inflammatory pathways and favorable in vivo activity.
  • AbCellera has a strong balance sheet (roughly $700M+ in liquidity per recent reports) and could potentially resume or partner ABCL575 in the future if strategic priorities shift.
Bear case
  • AbCellera has shelved ABCL575 development entirely as of November 2026, with no timeline for resumption.
  • The atopic dermatitis treatment market is highly competitive, with multiple approved biologics (Dupixent, Adbry, etc.) and other OX40-targeting drugs in development.
  • ABCL575 was only in Phase 1; it had not yet generated any efficacy data in humans, so its therapeutic profile remains unproven.
● neutral
Impact
PhasePreclinical / IND-enabling
Time to marketNot stated

ABCL688 Updated Nov 10

What to watch

ABCL688 appears to have been deprioritized or shelved as of AbCellera's Q3 2026 update. The company is focusing its resources on advancing ABCL635 (hot flash antibody) into Phase 3 in 2027. Investors should watch for any mention of ABCL688 in future earnings calls or corporate presentations to see if development resumes, but for now the program appears inactive.

Bull case
  • AbCellera has a strong antibody discovery platform and a growing cash position (raised $200M after ABCL635 Phase 2 data), which could allow it to revisit ABCL688 later.
  • The program reached IND-enabling studies, suggesting sufficient preclinical proof-of-concept to justify regulatory filing preparation.
  • AbCellera has multiple partnered programs generating revenue ($10.6M in Q3 2026) that could support pipeline expansion.
Bear case
  • ABCL688 appears to have been shelved as of Q3 2026, with no active development or clinical trials underway.
  • The specific target, mechanism, and indication have never been publicly disclosed, making it impossible to assess competitive positioning or market opportunity.
  • AbCellera is prioritizing ABCL635 (hot flashes) and ABCL575 (atopic dermatitis), leaving ABCL688 as a lower-priority preclinical asset with no near-term catalysts.
● neutral
Impact
PhaseNo data found for ABCL385
Time to marketNot stated

ABCL385 Updated Nov 12

What to watch

No information could be found on a drug called ABCL385. AbCellera's lead proprietary programs are ABCL635 (menopause/hot flashes, Phase 2 complete, Phase 3 planned for 2027) and ABCL575 (atopic dermatitis, Phase 1). The next major catalyst for ABCL is the Phase 3 initiation for ABCL635 expected in 2027, plus the UBS Global Biopharma Conference presentation on November 17, 2026.

Bull case
  • AbCellera has a strong balance sheet and analyst consensus is bullish: 16 Buy/Strong Buy ratings vs 2 Hold, with a mean price target of $18 (44.5% upside from $12.46).
  • Lead program ABCL635 showed positive Phase 2 data for menopausal hot flashes in August 2026, with Phase 3 planned for 2027, representing a large addressable market.
  • Insiders have been buying shares in 2026, including the CFO and directors, signaling confidence. Institutional accumulation from Bank of America and Marshall Wace in Q2 2026.
Bear case
  • No public information exists for a drug called ABCL385, suggesting it may be a very early preclinical program, a discontinued candidate, or a typo. AbCellera has a history of pipeline setbacks, recently abandoning its OX40 antibody program.
  • AbCellera reported a Q3 2026 net loss of $40.8 million with only $10.6 million in revenue, indicating significant cash burn with no approved products generating meaningful revenue.
  • The stock has a 6-month return of +150%, meaning much optimism may already be priced in ahead of late-stage clinical data for ABCL635.
● neutral
Impact
PhaseUnknown / Not publicly disclosed
Time to marketNot estimable; the drug candidate has no public presence.

ABCL386 Updated Nov 10

What to watch

No actionable catalyst exists for ABCL386 because the drug candidate could not be identified in any public source. Investors should verify the correct drug code; AbCellera's next major catalyst is the advancement of ABCL635 into Phase 3 development, which the company guided for 2027 after positive Phase 2 data reported in August 2026.

Bull case
  • No bull case can be constructed because ABCL386 does not appear in any public source as a real drug candidate from AbCellera Biologics.
Bear case
  • The drug code ABCL386 could not be found in any SEC filing, clinical trial registry, press release, news article, or analyst report, suggesting it may be a typo, an internal code that was never publicly disclosed, or a candidate that was discontinued before public announcement.
  • AbCellera's known proprietary pipeline consists only of ABCL635 (Phase 2, hot flashes) and ABCL575 (Phase 1, atopic dermatitis); no third proprietary candidate has been publicly named.
● neutral
Impact
PhaseUnknown / Not found
Time to marketNot stated

ABCL646 Updated Nov 12

What to watch

No information exists for "ABCL646" in any public source. Investors should verify the correct drug name; AbCellera's known pipeline includes ABCL635 (Phase 2 hot-flash antibody, advancing to Phase 3 in 2027) and ABCL575 (Phase 1 atopic-dermatitis antibody, recently shelved).

Bull case
  • No evidence of this drug candidate could be found to construct a bull case.
Bear case
  • The drug name 'ABCL646' does not appear in any public database, SEC filing, clinical trial registry, news source, or company pipeline disclosure, suggesting it may not exist, may be a very early undisclosed preclinical candidate, or may be a typographical error.
  • AbCellera's known internal pipeline is limited to two disclosed programs (ABCL635 and ABCL575), and the company recently shelved one of them (ABCL575/OX40L), indicating pipeline risk and a narrowing of internal development focus.
● neutral
Impact
PhaseNot publicly disclosed
Time to marketNot stated

ABCL992 Updated Nov 12

What to watch

ABCL992 does not appear in any public disclosure, SEC filing, clinical trial registry, or news source for AbCellera Biologics. Investors should verify the drug name with the company directly. AbCellera's actual disclosed pipeline consists of ABCL635 (Phase 2, lead), ABCL575 (Phase 1, shelved), and ABCL688 (preclinical, deprioritized). No catalyst exists for ABCL992 because the program has not been publicly identified.

Bull case
  • AbCellera Biologics (ABCL) is a well-capitalized antibody discovery company with over $890M in liquidity as of Q3 2026, giving it resources to fund early-stage programs.
  • The company has a validated platform with a major partnership with Vertex Pharmaceuticals (upfront $28M for T-cell engagers) and a lead asset (ABCL635) with positive Phase 2 data.
  • Analyst consensus on ABCL is strongly bullish: 16 Buy/Strong Buy ratings vs 2 Hold, with a mean price target of $18 (44.5% upside from $12.46).
Bear case
  • ABCL992 is not mentioned in any SEC filing, clinical trial registry, press release, or news article for AbCellera Biologics, suggesting it may not exist as a disclosed program.
  • AbCellera has been deprioritizing non-core pipeline programs: it shelved ABCL575 (Phase 1, atopic dermatitis) and deprioritized ABCL688 (preclinical) to focus resources on lead asset ABCL635.
  • Without any disclosed data, target, or indication, there is no basis to evaluate ABCL992's therapeutic or commercial potential.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ABCL635Study Evaluating ABCL635 for Vasomotor Symptoms of MenopausePhase 2Active not recruiting136Feb 2027